Search

Your search keyword '"Imajo, Kento"' showing total 658 results
Start Over Author "Imajo, Kento"
658 results on '"Imajo, Kento"'

151. Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility

Author

Kato, Shingo, primary, Iwasaki, Akito, additional, Kurita, Yusuke, additional, Arimoto, Jun, additional, Yamamoto, Toh, additional, Hasegawa, Sho, additional, Sato, Takamitsu, additional, Imajo, Kento, additional, Hosono, Kunihiro, additional, Kobayashi, Noritoshi, additional, Yoneda, Masato, additional, Higurashi, Takuma, additional, Kubota, Kensuke, additional, Utsunomiya, Daisuke, additional, and Nakajima, Atsushi, additional

Published
2019
Full Text
View/download PDF

152. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study

Author

Oeda, Satoshi, primary, Takahashi, Hirokazu, additional, Imajo, Kento, additional, Seko, Yuya, additional, Ogawa, Yuji, additional, Moriguchi, Michihisa, additional, Yoneda, Masato, additional, Anzai, Keizo, additional, Aishima, Shinichi, additional, Kage, Masayoshi, additional, Itoh, Yoshito, additional, Nakajima, Atsushi, additional, and Eguchi, Yuichiro, additional

Published
2019
Full Text
View/download PDF

153. Relationship between Stool Form and Quality of Life in Patients with Chronic Constipation: An Internet Questionnaire Survey

Author

Ohkubo, Hidenori, primary, Yoshihara, Tsutomu, additional, Misawa, Noboru, additional, Ashikari, Keiichi, additional, Fuyuki, Akiko, additional, Matsuura, Tetsuya, additional, Higurashi, Takuma, additional, Imajo, Kento, additional, Hosono, Kunihiro, additional, Yoneda, Masato, additional, Kobayashi, Noritoshi, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2019
Full Text
View/download PDF

154. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: The GOASIA study

Author

Pitisuttithum, Panyavee, primary, Chan, Wah Kheong, additional, Piyachaturawat, Panida, additional, Imajo, Kento, additional, Nakajima, Atsushi, additional, Seki, Yosuke, additional, Kasama, Kazunori, additional, Kakizaki, Satoru, additional, Fan, Jian Gao, additional, Song, Myeong Jun, additional, Yoon, Seung Kew, additional, Dan, Yock Young, additional, Lesmana, Laurentius, additional, Ho, Khek Yu, additional, Goh, Khean Lee, additional, Wong, Vincent Wai Sun, additional, and Treeprasertsuk, Sombat, additional

Published
2019
Full Text
View/download PDF

155. Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: A proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study

Author

Ozaki, Anna, primary, Kessoku, Takaomi, additional, Iwaki, Michihiro, additional, Kobayashi, Takashi, additional, Yoshihara, Tsutomu, additional, Kato, Takayuki, additional, Honda, Yasushi, additional, Ogawa, Yuji, additional, Imajo, Kento, additional, Higurashi, Takuma, additional, Yoneda, Masato, additional, Taguri, Masataka, additional, Yamanaka, Takeharu, additional, Ishiki, Hiroto, additional, Saito, Satoru, additional, Ichikawa, Yasushi, additional, and Nakajima, Atsushi, additional

Published
2019
Full Text
View/download PDF

157. Infection phase is a predictor of pruritus in patients with hepatitis B virus infection

Author

Oeda, Satoshi, primary, Takahashi, Hirokazu, additional, Isoda, Hiroshi, additional, Komukai, Sho, additional, Imajo, Kento, additional, Yoneda, Masato, additional, Ono, Masafumi, additional, Hyogo, Hideyuki, additional, Kawaguchi, Takumi, additional, Fujii, Hideki, additional, Kawanaka, Miwa, additional, Sumida, Yoshio, additional, Tanaka, Saiyu, additional, Kawamoto, Hirofumi, additional, Torimura, Takuji, additional, Saibara, Toshiji, additional, Kawaguchi, Atsushi, additional, Nakajima, Atsushi, additional, and Eguchi, Yuichiro, additional

Published
2019
Full Text
View/download PDF

158. Assessment of 10‐year changes in liver stiffness using vibration‐controlled transient elastography in non‐alcoholic fatty liver disease

Author

Nogami, Asako, primary, Yoneda, Masato, additional, Kobayashi, Takashi, additional, Kessoku, Takaomi, additional, Honda, Yasushi, additional, Ogawa, Yuji, additional, Suzuki, Kaori, additional, Tomeno, Wataru, additional, Imajo, Kento, additional, Kirikoshi, Hiroyuki, additional, Koide, Tomoko, additional, Fujikawa, Hirotoshi, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2019
Full Text
View/download PDF

159. GS-01-Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, doubleblind, randomized, placebo-controlled, phase II study

Author

Kessoku, Takaomi, primary, Imajo, Kento, additional, Ogawa, Yuji, additional, Kobayashi, Takashi, additional, Honda, Yasushi, additional, Kato, Takayuki, additional, Tomeno, Wataru, additional, Kato, shingo, additional, Higurashi, Takuma, additional, Yoneda, Masato, additional, Kirikoshi, Hiroyuki, additional, Kubota, Kazumi, additional, Taguri, Masataka, additional, Yamanaka, Takeharu, additional, Usuda, Haruki, additional, Wada, Koichiro, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2019
Full Text
View/download PDF

162. FRI-312-Increased levels of bile acid in feces plays an important role in pathophysiology of non-alcoholic steatohepatitis

Author

Kessoku, Takaomi, primary, Kobayashi, Takashi, additional, Imajo, Kento, additional, Honda, Yasushi, additional, Ogawa, Yuji, additional, Higurashi, Takuma, additional, Kato, Shingo, additional, Yoneda, Masato, additional, Oikawa, Yousuke, additional, Tanaka, Yoshiki, additional, Nakajima, Shunji, additional, Usuda, Haruki, additional, Wada, Koichiro, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2019
Full Text
View/download PDF

164. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis

Author

Kodama, Kazuhisa, primary, Kawaguchi, Takumi, additional, Hyogo, Hideyuki, additional, Nakajima, Tomoaki, additional, Ono, Masafumi, additional, Seike, Masataka, additional, Takahashi, Hirokazu, additional, Nozaki, Yuichi, additional, Kawanaka, Miwa, additional, Tanaka, Saiyu, additional, Imajo, Kento, additional, Sumida, Yoshio, additional, Kamada, Yoshihiro, additional, Fujii, Hideki, additional, Seko, Yuya, additional, Takehara, Tetsuo, additional, Itoh, Yoshito, additional, Nakajima, Atsushi, additional, Masaki, Naohiko, additional, Torimura, Takuji, additional, Saibara, Toshiji, additional, Karino, Yoshiyasu, additional, Chayama, Kazuaki, additional, and Tokushige, Katsutoshi, additional

Published
2019
Full Text
View/download PDF

165. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index

Author

Tomeno, Wataru, primary, Imajo, Kento, additional, Kuwada, Yukiko, additional, Ogawa, Yuji, additional, Kikuchi, Minako, additional, Honda, Yasushi, additional, Kato, Takayuki, additional, Kessoku, Takaomi, additional, Kirikoshi, Hiroyuki, additional, Yoneda, Masato, additional, Kitahora, Tetsuji, additional, Saito, Satoru, additional, Ozawa, Yukihiko, additional, and Nakajima, Atsushi, additional

Published
2019
Full Text
View/download PDF

166. Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study

Author

Abe Yasunobu, Takahashi Hirokazu, Kanesaki Akira, Sawabe Aya, Atsukawa Kazuhiro, Sakaguchi Takashi, Imajo Kento, Higurashi Takuma, Uchiyama Takashi, Mawatari Hironori, Fujita Koji, Yoneda Masato, Saito Satoru, Kirikoshi Hiroyuki, Inamori Masahiko, Kobayashi Noritoshi, Kubota Kensuke, Ueno Norio, and Nakajima Atsushi

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background Spontaneous rupture is rare complication of hepatocellular carcinoma (HCC) with high mortality rate in cirrhotic cases. The aim of this study was to determine the factors influencing prognosis in cases of spontaneously ruptured HCC and to investigate the outcomes of the treatments employed, especially transcatheter arterial embolization (TAE). Methods A retrospective multicenter study was conducted in 48 cirrhotic patients with spontaneous rupture of HCC. Conservative treatment was employed in 32 patients (ConT group) and TAE was performed in 16 patients (TAE group). Results The median survival time (MST) in the ConT group was only 13.1 days and the survival rate was extremely poor: 59.4% at 7 days, 37.5% at 14 days, and 6.3% at 30 days. On the other hand, the MST in the TAE group was 244.8 days and the survival rate was 87.5% at 1 month, 56.3% at 3 months, 23.4% at 12 months, and 15.6% at 24 months. According to the results of univariate analyses, factors associated with poor hepatic function and poor suitability for TAE was important determinants of short-term death (less than 3 weeks) among the patients (p < 0.05). On the other hand, among the patients in whom initial TAE was successfully performed (n = 15), a multivariate analysis showed that a maximum tumor size not exceeding 7 cm was the only independent factor determining long-term survival (p = 0.0130). Conclusion Despite the inherent limitations of this retrospective study, TAE appears to be a useful treatment strategy for cirrhotic patients with spontaneous HCC rupture, as it yielded a longer survival period compared with conservative treatment in patients with ruptured HCC. Among the patients with ruptured HCC in whom initial TAE was successfully performed, the maximum tumor size was an important factor influencing survival.

Published
2009
Full Text
View/download PDF

167. Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes.

Author

Ishiba, Hiroshi, Sumida, Yoshio, Seko, Yuya, Tanaka, Saiyu, Yoneda, Masato, Hyogo, Hideyuki, Ono, Masafumi, Fujii, Hideki, Eguchi, Yuichiro, Suzuki, Yasuaki, Yoneda, Masashi, Takahashi, Hirokazu, Nakahara, Takashi, Mori, Kojiro, Kanemasa, Kazuyuki, Shimada, Keiji, Imajo, Kento, Yamaguchi, Kanji, Kawaguchi, Takumi, and Nakajima, Atsushi

Subjects
COLLAGEN, HEPATIC fibrosis, TYPE 2 diabetes
Abstract

This study aimed to examine whether the diagnostic accuracy of four noninvasive tests (NITs) for detecting advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is maintained or is inferior to with or without the presence of type 2 diabetes. Overall, 874 patients with biopsy‐proven NAFLD were enrolled. After propensity‐score matching by age, sex, and the prevalence of dyslipidemia, 311 patients were enrolled in each group of with or without diabetes. To evaluate the effect of diabetes, we compared the diagnostic accuracy of the fibrosis‐4 (FIB‐4) index, the NAFLD fibrosis score (NFS), the aspartate aminotransferase to platelet ratio index (APRI), and type IV collagen 7S (COL4‐7S) in patients with NAFLD with and without diabetes. The areas under the receiver operating characteristic curve (AUROC) for identifying advanced fibrosis in patients without diabetes were 0.879 for the FIB‐4 index, 0.851 for the NFS, 0.862 for the APRI, and 0.883 for COL4‐7S. The AUROCs in patients with diabetes were 0.790 for the FIB‐4 index, 0.784 for the NFS, 0.771 for the APRI, and 0.872 for COL4‐7S. The AUROC of COL4‐7S was significantly larger than that of the other NITs in patients with NAFLD with diabetes than in those without diabetes. The optimal high and low cutoff points of COL4‐7S were 5.9 ng/mL and 4.8 ng/mL, respectively. At the low cutoff point, the accuracy of COL4‐7S was better than that of the other NITs, especially in patients with diabetes. Conclusion: COL4‐7S measurement might be the best NIT for identifying advanced fibrosis in NAFLD, especially in NAFLD with diabetes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

168. Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin

Author

Ogawa Yuji, Imajo Kento, Honda Yasushi, Kessoku Takaomi, Tomeno Wataru, Kato Shingo, Fujita Koji, Yoneda Masato, Saito Satoru, Saigusa Yusuke, Hyogo Hideyuki, Sumida Yoshio, Itoh Yoshito, Eguchi Kosei, Yamanaka Takeharu, Wada, Koichiro, Nakajima Atsushi, Ogawa Yuji, Imajo Kento, Honda Yasushi, Kessoku Takaomi, Tomeno Wataru, Kato Shingo, Fujita Koji, Yoneda Masato, Saito Satoru, Saigusa Yusuke, Hyogo Hideyuki, Sumida Yoshio, Itoh Yoshito, Eguchi Kosei, Yamanaka Takeharu, Wada, Koichiro, and Nakajima Atsushi

Published
2018

170. Relationship between Stool Form and Quality of Life in Patients with Chronic Constipation: An Internet Questionnaire Survey.

Author

Ohkubo, Hidenori, Yoshihara, Tsutomu, Misawa, Noboru, Ashikari, Keiichi, Fuyuki, Akiko, Matsuura, Tetsuya, Higurashi, Takuma, Imajo, Kento, Hosono, Kunihiro, Yoneda, Masato, Kobayashi, Noritoshi, Saito, Satoru, and Nakajima, Atsushi

Subjects
INTERNET surveys, CONSTIPATION, PATIENT satisfaction, DRUG utilization, QUALITY of life
Abstract

Introduction: Chronic constipation (CC) is a highly prevalent functional bowel disorder with low treatment satisfaction and impaired quality of life (QOL). However, physicians tend to emphasize only "stool frequency," and relationship between "stool form" and QOL remains unclear. In this study, we aimed to investigate the actual situation of CC treatment in Japan and elucidate the relationship between stool form and QOL in patients with CC. Methods: We conducted an online questionnaire survey in September 2018 targeting Japanese adult patients already diagnosed with CC and taking prescribed drugs. Assessments included the type of drug treatment, treatment duration, frequency of drug use, frequency of bowel movements (BMs), Bristol Stool Form Scale (BSFS), and Japanese version of the Patient Assessment of Constipation QOL (PAC-QOL) scores. Relationship between BSFS and Japanese PAC-QOL scores was analyzed, and most important factor that influences QOL was investigated. Results: A total of 614 subjects were enrolled. Of these, 398 (64.8%) regularly used magnesium oxide and 162 (26.4%) used stimulant laxative, especially 81 (50.0%) used stimulant laxative "everyday." Mean score of the PAC-QOL was 1.29 ± 0.74, and the lowest score (highest QOL) of 0.94 ± 0.61 was observed in BSFS type 4. Significant difference was seen between BSFS type 4 and all the other types except type 7. Multivariate analysis revealed that normal stool form (BSFS type 4) and BMs ≥3/week are strongly related to decreases of PAC-COL score. In BSFS types 6 and 7, 36% of individuals experienced self-discontinuation of prescribed drugs and 53% self-reduced drug intake because of excessive effects. Conclusions: Stool form and frequency of BMs are relevant to QOL, especially normal stool form (BSFS type 4) is important for improving the QOL in patients with constipation. Physicians should focus on "stool form" and reconsider the prescription especially in BSFS types 6–7 patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

171. Eradication of hepatitis C virus with direct‐acting antivirals improves glycemic control in diabetes: A multicenter study.

Author

Takahashi, Hirokazu, Nakahara, Takashi, Kogiso, Tomomi, Imajo, Kento, Kessoku, Takaomi, Kawaguchi, Takumi, Ide, Tatsuya, Kawanaka, Miwa, Hyogo, Hideyuki, Fujii, Hideki, Ono, Masafumi, Kamada, Yoshihiro, Sumida, Yoshio, Anzai, Keizo, Shimizu, Masahito, Torimura, Takuji, Nakajima, Atsushi, Tokushige, Katsutoshi, Chayama, Kazuaki, and Eguchi, Yuichiro

Subjects
HEPATITIS C virus, GLYCEMIC control, DIABETES
Abstract

Background and Aim: Hepatitis C virus (HCV) infection causes insulin resistance and diabetes as extrahepatic manifestations. We aimed to analyze the effect of HCV eradication by direct‐acting antiviral (DAA) agents on glucose tolerance. Methods: The hemoglobin A1c (HbA1c) of 272 patients with HCV infection who achieved a sustained virologic response (SVR) was analyzed at baseline before DAA treatment, at the end of DAA therapy (ETR), and 12 weeks after therapy (Post12W). Results: There were no significant differences in HbA1c between baseline, ETR, and Post12W in the overall patients. When the data were stratified according to the presence or absence of diabetes, median HbA1c significantly decreased from baseline (7.2%) to ETR (6.8%) and Post12W (6.8%) in the 55 patients with diabetes, whereas there were no significant changes in the patients without diabetes. Basal HbA1c, fasting plasma glucose, and age were independently associated with the changes in HbA1c according to multivariate analysis, and the predictive formula for changes in HbA1c was found to be ΔHbA1c (%) = 1.449–0.4* HbA1c (%) + 0.012 × Age (year). There were no changes in body mass in diabetic or nondiabetic patients. In diabetic patients taking medication, 63.4% of patients needed less medication. Conclusions: Eradication of HCV improves glycemic control, indicated by a 0.4% decrease in HbA1c in diabetes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

172. Discordant pathological diagnosis of non‐alcoholic fatty liver disease: A prospective multicenter study.

Author

Kuwashiro, Takuya, Takahashi, Hirokazu, Hyogo, Hideyuki, Ogawa, Yuji, Imajo, Kento, Yoneda, Masato, Nakahara, Takashi, Oeda, Satoshi, Tanaka, Kenichi, Amano, Yuichiro, Ogawa, Shinji, Kawaguchi, Atsushi, Aishima, Shinichi, Kage, Masayoshi, Chayama, Kazuaki, Nakajima, Atsushi, and Eguchi, Yuichiro

Subjects
FATTY liver, LIVER biopsy, LONGITUDINAL method
Abstract

Background: Liver biopsy has been the standard procedure for diagnosing and evaluating the severity of non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH); however, interobserver discordance remains a critical issue in its pathological diagnosis. Methods and Results: We examined the concordance rates of pathological scoring and diagnosis between pathologists at individual institutions (local diagnosis) and two central pathologists specialized in liver pathology (central diagnosis). A total of 150 patients with NAFLD underwent prospective liver biopsies. NAFLD activity score (NAS) and fibrosis stage were evaluated, and NASH was determined according to Matteoni's classification. NAS, scores for all NAS components, and fibrosis stage were diagnosed at a lower degree by central compared with local diagnosis. NASH was diagnosed in 34% of the patients according to central pathologists compared with 54% according to local pathologists (P < 0.001). The concordance rates for NAS, steatosis, inflammation, ballooning, fibrosis, and NASH diagnosis were 26.7, 62.7, 51.3, 48.7, 43.3, and 50.7%, respectively. The correlation coefficient between local and central diagnoses was the lowest for the scoring of ballooning (ρ = 0.218). Conclusion: Concordance rates among pathologists for the evaluation of NAFLD are currently poor, and simple and reliable diagnostic and evaluation criteria are urgently needed to improve the clinical management of NAFLD patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

173. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study.

Author

Oeda, Satoshi, Takahashi, Hirokazu, Imajo, Kento, Seko, Yuya, Ogawa, Yuji, Moriguchi, Michihisa, Yoneda, Masato, Anzai, Keizo, Aishima, Shinichi, Kage, Masayoshi, Itoh, Yoshito, Nakajima, Atsushi, and Eguchi, Yuichiro

Subjects
FATTY liver, FATTY degeneration, FIBROSIS, LONGITUDINAL method, LIVER, PATHOLOGISTS
Abstract

Background: Few studies have evaluated both liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD) using both FibroScan® M and XL probes. This study was performed to investigate the accuracy of both FibroScan® probes to diagnose liver fibrosis and steatosis in patients with NAFLD.Methods: We prospectively enrolled 137 consecutive patients with clinically suspected NAFLD in our joint-research facilities. Liver biopsies, liver stiffness measurements (LSMs), and controlled attenuation parameter (CAP) measurements were performed, and 122 patients with NAFLD diagnosed pathologically by central pathologists were included in the final analysis.Results: Reliable LSM results were obtained in 85.2% (M) and 89.3% (XL) of patients, and CAP was reliable in 90.2% (M) and 90.2% (XL). The median LSM was significantly lower with the XL than M probe, and CAP was significantly higher with the XL than M probe. The optimal cut-off values for diagnosing the fibrosis stage were lower for LSM with the XL than M probe (stage ≥ 2, 6.7 vs. 7.0; stage ≥ 3, 8.2 vs. 10.8; stage 4, 14.3 vs. 16.8, respectively), whereas those of CAP were higher for the XL than M probe (score of ≥ 2, 273 vs. 267; score of 3, 302 vs. 286, respectively). There were no significant differences in accuracy of the LSM and CAP between the probes.Conclusions: Liver fibrosis and steatosis could be equally evaluated with FibroScan® M and XL probes in patients with NAFLD. There was no significant difference in diagnostic accuracy between the two probes using probe-specific cut-off values. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

176. Magnetic resonance elastography increases usefulness and safety of non‐invasive screening for esophageal varices

Author

Matsui, Nobuaki, primary, Imajo, Kento, additional, Yoneda, Masato, additional, Kessoku, Takaomi, additional, Honda, Yasushi, additional, Ogawa, Yuji, additional, Tomeno, Wataru, additional, Fujisawa, Nobutaka, additional, Misumi, Toshihiro, additional, Kazumi, Kubota, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2018
Full Text
View/download PDF

177. New microwave ablation system for unresectable liver tumors that forms large, spherical ablation zones

Author

Imajo, Kento, primary, Tomeno, Wataru, additional, Kanezaki, Mineo, additional, Honda, Yasushi, additional, Kessoku, Takaomi, additional, Ogawa, Yuji, additional, Yoshida, Keisuke, additional, Yoneda, Masato, additional, Kirikoshi, Hiroyuki, additional, Ono, Masafumi, additional, Kaneta, Tomohiro, additional, Inoue, Tomio, additional, Teratani, Takuma, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2018
Full Text
View/download PDF

178. Wisteria floribundaagglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease

Author

Ogawa, Yuji, primary, Honda, Yasushi, additional, Kessoku, Takaomi, additional, Tomeno, Wataru, additional, Imajo, Kento, additional, Yoneda, Masato, additional, Kawanaka, Miwa, additional, Kirikoshi, Hiroyuki, additional, Ono, Masafumi, additional, Taguri, Masataka, additional, Saito, Satoru, additional, Yamanaka, Takeharu, additional, Wada, Koichiro, additional, and Nakajima, Atsushi, additional

Published
2018
Full Text
View/download PDF

179. Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue

Author

Ohki, Kohji, primary, Wakui, Hiromichi, additional, Kishio, Nozomu, additional, Azushima, Kengo, additional, Uneda, Kazushi, additional, Haku, Sona, additional, Kobayashi, Ryu, additional, Haruhara, Kotaro, additional, Kinguchi, Sho, additional, Yamaji, Takahiro, additional, Yamada, Takayuki, additional, Minegishi, Shintaro, additional, Ishigami, Tomoaki, additional, Toya, Yoshiyuki, additional, Yamashita, Akio, additional, Imajo, Kento, additional, Nakajima, Atsushi, additional, Kato, Ikuma, additional, Ohashi, Kenichi, additional, and Tamura, Kouichi, additional

Published
2018
Full Text
View/download PDF

180. Gut microbiota and nonalcoholic steatohepatitis

Author

Kessoku, Takaomi, primary, Imajo, Kento, additional, Kobayashi, Takashi, additional, Honda, Yasushi, additional, Ogawa, Yuji, additional, Yoneda, Masato, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2018
Full Text
View/download PDF

181. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study

Author

00202094, Honda, Yasushi, Kessoku, Takaomi, Sumida, Yoshio, Kobayashi, Takashi, Kato, Takayuki, Ogawa, Yuji, Tomeno, Wataru, Imajo, Kento, Fujita, Koji, Yoneda, Masato, Kataoka, Koshi, Taguri, Masataka, Yamanaka, Takeharu, Seko, Yuya, Tanaka, Saiyu, Saito, Satoru, Ono, Masafumi, Oeda, Satoshi, Eguchi, Yuichiro, Aoi, Wataru, Sato, Kenji, Itoh, Yoshito, Nakajima, Atsushi, 00202094, Honda, Yasushi, Kessoku, Takaomi, Sumida, Yoshio, Kobayashi, Takashi, Kato, Takayuki, Ogawa, Yuji, Tomeno, Wataru, Imajo, Kento, Fujita, Koji, Yoneda, Masato, Kataoka, Koshi, Taguri, Masataka, Yamanaka, Takeharu, Seko, Yuya, Tanaka, Saiyu, Saito, Satoru, Ono, Masafumi, Oeda, Satoshi, Eguchi, Yuichiro, Aoi, Wataru, Sato, Kenji, Itoh, Yoshito, and Nakajima, Atsushi

Abstract

Background: Glutathione plays crucial roles in the detoxification and antioxidant systems of cells and has been used to treat acute poisoning and chronic liver diseases by intravenous injection. This is a first study examining the therapeutic effects of oral administration of glutathione in patients with nonalcoholic fatty liver disease (NAFLD). Methods: The study was an open label, single arm, multicenter, pilot trial. Thirty-four NAFLD patients diagnosed using ultrasonography were prospectively evaluated. All patients first underwent intervention to improve their lifestyle habits (diet and exercise) for 3 months, followed by treatment with glutathione (300 mg/day) for 4 months. We evaluated their clinical parameters before and after glutathione treatment. We also quantified liver fat and fibrosis using vibration-controlled transient elastography. The primary outcome of the study was the change in alanine aminotransferase (ALT) levels. Results: Twenty-nine patients finished the protocol. ALT levels significantly decreased following treatment with glutathione for 4 months. In addition, triglycerides, non-esterified fatty acids, and ferritin levels also decreased with glutathione treatment. Following dichotomization of ALT responders based on a median 12.9% decrease from baseline, we found that ALT responders were younger in age and did not have severe diabetes compared with ALT non-responders. The controlled attenuation parameter also decreased in ALT responders. Conclusions: This pilot study demonstrates the potential therapeutic effects of oral administration of glutathione in practical dose for patients with NAFLD. Large-scale clinical trials are needed to verify its efficacy. Trial registration: UMIN000011118 (date of registration: July 4, 2013).

Published
2017

183. LBP26 - Resolution of non-alcoholic steatohepatitis and hepatic fibrosis by sodium glucose transporter-2 inhibitor, ipragliflozin; a multicenter randomized controlled trial

Author

Takahashi, Hirokazu, Kessoku, Takaomi, Kawanaka, Miwa, Nonaka, Michihiro, Hyogo, Hideyuki, Fujii, Hideki, Nakajima, Tomoaki, Imajo, Kento, Tanaka, Kenichi, Kubotsu, Yoshihito, Isoda, Hiroshi, Oeda, Satoshi, Kurai, Osamu, Yoneda, Masato, Ono, Masafumi, Kitajima, Yoichiro, Tajiri, Ryo, Takamori, Ayako, Kawaguchi, Atsushi, Aishima, Shinichi, Kage, Masayoshi, Anzai, Keizo, Nakajima, Atsushi, and Eguchi, Yuichiro

Published
2020
Full Text
View/download PDF

186. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study

Author

Honda, Yasushi, primary, Kessoku, Takaomi, additional, Sumida, Yoshio, additional, Kobayashi, Takashi, additional, Kato, Takayuki, additional, Ogawa, Yuji, additional, Tomeno, Wataru, additional, Imajo, Kento, additional, Fujita, Koji, additional, Yoneda, Masato, additional, Kataoka, Koshi, additional, Taguri, Masataka, additional, Yamanaka, Takeharu, additional, Seko, Yuya, additional, Tanaka, Saiyu, additional, Saito, Satoru, additional, Ono, Masafumi, additional, Oeda, Satoshi, additional, Eguchi, Yuichiro, additional, Aoi, Wataru, additional, Sato, Kenji, additional, Itoh, Yoshito, additional, and Nakajima, Atsushi, additional

Published
2017
Full Text
View/download PDF

187. The High Prevalence and Predictors of Advance Fibrosis in Elderly Patients with Liver Biopsy Confirmed Non-Alcoholic Fatty Liver Disease (NAFLD): The Goasia Study

Author

Pitisuttithum, Panyavee, primary, Chan, Wah-Kheong, additional, Imajo, Kento, additional, Nakajima, Atsushi, additional, Seki, Yosuke, additional, Kasama, Kazunori, additional, Kakizaki, Satoru, additional, Fan, Jian Gao, additional, Song, Myeong Jun, additional, Yoon, Seung Kew, additional, Dan, Yock Young, additional, Lesmana, Laurentius A., additional, Ho, Khek-Yu, additional, Goh, Khean Lee, additional, Wong, Vincent, additional, and Treeprasertsuk, Sombat, additional

Published
2017
Full Text
View/download PDF

188. Characteristics of Fecal Microbiota in Japanese Patients with Nonalcoholic Fatty Liver Disease: A Connection among Gut-Permeability, Endotoxin and NAFLD

Author

Kessoku, Takaomi, primary, Imajo, Kento, additional, Honda, Yasushi, additional, Kato, Takayuki, additional, Ogawa, Yuji, additional, Tomeno, Wataru, additional, Higurashi, Takuma, additional, Yoneda, Masato, additional, Shimakawa, Masaki, additional, Tanaka, Yoshiki, additional, Kawahara, Tomohiro, additional, Saito, Satoru, additional, Haruki, Usuda, additional, Wada, Koichiro, additional, and Nakajima, Atsushi, additional

Published
2017
Full Text
View/download PDF

189. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis

Author

Honda, Yasushi, primary, Kessoku, Takaomi, additional, Ogawa, Yuji, additional, Tomeno, Wataru, additional, Imajo, Kento, additional, Fujita, Koji, additional, Yoneda, Masato, additional, Takizawa, Toshiaki, additional, Saito, Satoru, additional, Nagashima, Yoji, additional, and Nakajima, Atsushi, additional

Published
2017
Full Text
View/download PDF

190. A case of Castleman disease complicating chronic hepatitis C

Author

Tomeno, Wataru, primary, Niikura, Toshihiro, additional, Okudera, Koji, additional, Ogawa, Yuji, additional, Honda, Yasushi, additional, Kessoku, Takaomi, additional, Imajo, Kento, additional, Yoneda, Masato, additional, Kirikoshi, Hiroyuki, additional, Yamanaka, Shoji, additional, Ohashi, Kenichi, additional, Nakajima, Atsushi, additional, and Saito, Satoru, additional

Published
2017
Full Text
View/download PDF

191. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial

Author

Kessoku, Takaomi, Imajo, Kento, Kobayashi, Takashi, Ozaki, Anna, Iwaki, Michihiro, Honda, Yasushi, Kato, Takayuki, Ogawa, Yuji, Tomeno, Wataru, Kato, Shingo, Higurashi, Takuma, Yoneda, Masato, Kirikoshi, Hiroyuki, Kubota, Kazumi, Taguri, Masataka, Yamanaka, Takeharu, Usuda, Haruki, Wada, Koichiro, Kobayashi, Noritoshi, Saito, Satoru, and Nakajima, Atsushi

Abstract

The laxative drug lubiprostone improves intestinal permeability in healthy volunteers. We aimed to assess efficacy and safety of lubiprostone in patients with non-alcoholic fatty liver disease (NAFLD) with constipation via attenuation of intestinal permeability.

Published
2020
Full Text
View/download PDF

192. HOMA‐IR: An independent predictor of advanced liver fibrosis in nondiabetic non‐alcoholic fatty liver disease.

Author

Fujii, Hideki, Imajo, Kento, Yoneda, Masato, Nakahara, Takashi, Hyogo, Hideyuki, Takahashi, Hirokazu, Hara, Tasuku, Tanaka, Saiyu, Sumida, Yoshio, Eguchi, Yuichiro, Chayama, Kazuaki, Nakajima, Atsushi, Nishimoto, Naoki, and Kawada, Norifumi

Subjects
*FATTY liver, *TYPE 2 diabetes, *FIBROSIS, *BODY mass index
Abstract

Background and Aim: Although non‐alcoholic fatty liver disease (NAFLD) is common in the general population, identifying patients with advanced fibrosis remains a challenge. We investigated whether the homeostasis model assessment parameter of insulin resistance (HOMA‐IR), an index of IR and one of the most important metabolic factors, is an independent predictive factor for advanced fibrosis in nondiabetic patients with NAFLD. Methods: This was a retrospective, cross‐sectional multicenter study. We included 361 patients with biopsy‐proven NAFLD who had not been diagnosed with type 2 diabetes mellitus: 175 (48%) were women and 48 (13%) had advanced fibrosis. We used simple random sampling; the sampling ratio of the estimation and validation groups was 7:3. A logistic model was constructed for both the estimation and validation groups. The explanatory variables were age ≥ 49 years, sex (women), body mass index ≥ 26.7 kg/m2, the presence of hypertension, presence of dyslipidemia, fasting plasma glucose level ≥ 98 mg/dL, fasting immune reactive insulin level ≥ 12.0 μU/mL, and HOMA‐IR ≥ 2.90. The median HOMA‐IR of the patients was 2.88 (interquartile range: 2.1–4.8). Results: In the estimation group, univariate and multivariate analyses showed that age, dyslipidemia, and HOMA‐IR were independent predictors of advanced fibrosis. In the validation group, only age and HOMA‐IR were found to be independent predictors of advanced fibrosis. Conclusions: Homeostasis model assessment parameter of insulin resistance was an independent predictor of advanced liver fibrosis in nondiabetic patients with NAFLD. Given that most patients with NAFLD are nondiabetic, it is important to set goals with respect to improving IR to subsequently reduce liver fibrosis. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

194. Reply

Author

Imajo, Kento, primary and Nakajima, Atsushi, additional

Published
2016
Full Text
View/download PDF

195. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation

Author

Takeda, Atsuya, primary, Sanuki, Naoko, additional, Tsurugai, Yuichiro, additional, Iwabuchi, Shogo, additional, Matsunaga, Kotaro, additional, Ebinuma, Hirotoshi, additional, Imajo, Kento, additional, Aoki, Yousuke, additional, Saito, Hidetsugu, additional, and Kunieda, Etsuo, additional

Published
2016
Full Text
View/download PDF

196. Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors

Author

Honda, Yasushi, primary, Yoneda, Masato, additional, Kessoku, Takaomi, additional, Ogawa, Yuji, additional, Tomeno, Wataru, additional, Imajo, Kento, additional, Mawatari, Hironori, additional, Fujita, Koji, additional, Hyogo, Hideyuki, additional, Ueno, Takato, additional, Chayama, Kazuaki, additional, Saito, Satoru, additional, Nakajima, Atsushi, additional, and Hotta, Kikuko, additional

Published
2016
Full Text
View/download PDF

197. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography

Author

Imajo, Kento, primary, Kessoku, Takaomi, additional, Honda, Yasushi, additional, Tomeno, Wataru, additional, Ogawa, Yuji, additional, Mawatari, Hironori, additional, Fujita, Koji, additional, Yoneda, Masato, additional, Taguri, Masataka, additional, Hyogo, Hideyuki, additional, Sumida, Yoshio, additional, Ono, Masafumi, additional, Eguchi, Yuichiro, additional, Inoue, Tomio, additional, Yamanaka, Takeharu, additional, Wada, Koichiro, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2016
Full Text
View/download PDF

198. Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis

Author

Kessoku, Takaomi, primary, Imajo, Kento, additional, Honda, Yasushi, additional, Kato, Takayuki, additional, Ogawa, Yuji, additional, Tomeno, Wataru, additional, Kato, Shingo, additional, Mawatari, Hironori, additional, Fujita, Koji, additional, Yoneda, Masato, additional, Nagashima, Yoji, additional, Saito, Satoru, additional, Wada, Koichiro, additional, and Nakajima, Atsushi, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results